Drugs & TargetsFree FDA issues draft guidance on patient-focused drug development July 01, 2022Vol.48 No.26
Drugs & Targets FDA grants accelerated approval to Tafinlar + Mekinist in unresectable or metastatic solid tumors with BRAF V600E mutation June 24, 2022Vol.48 No.25
Drugs & Targets FDA grants Fast Track designation to IK-930 in unresectable NF2-deficient mesothelioma June 24, 2022Vol.48 No.25
Drugs & Targets FDA campaign aims to prevent e-cigarette use among AI/AN youth June 10, 2022Vol.48 No.23
In Brief Reena Philip named associate director of biomarkers and precision oncology at OCE June 03, 2022Vol.48 No.22
Drugs & Targets FDA approves two Opdivo-based regimens in unresectable advanced or metastatic ESCC June 03, 2022Vol.48 No.22
Drugs & Targets FDA approves Kymriah in relapsed or refractory follicular lymphoma June 03, 2022Vol.48 No.22
Drugs & Targets FDA grants priority review to Omblastys in pediatric CNS/leptomeningeal metastasis from neuroblastoma June 03, 2022Vol.48 No.22
